 "America’s obesity rate drops, but diabetes reaches record high")
After years of rising numbers, America is finally seeing a small but meaningful decline in obesity. The shift comes alongside growing reliance on new weight loss medications and changing public attitudes toward health. Yet even as fewer adults are classified as obese, diabetes rates are climbing to record highs, raising questions about the long term impact of these medical trends.
Obesity declines but diabetes rises in the US
The adult obesity rate in the United States has dropped from a record 39.9 percent in 2022 to 37 percent in 2025, marking a significant reduction of nearly eight million people. However, diabetes cases have reached a new peak of 13.8 percent. This data, drawn from Gallup’s National Health and Well Being Index, shows that even as obesity rates improve, diabetes continues to climb due to its lifelong nature and multiple underlying causes.
Weight loss drugs gain immense popularity
Over the past year, Americans have increasingly turned to GLP 1 injectable medicines such as semaglutide, known under the brands Ozempic and Wegovy, to lose weight. The number of adults using these medicines specifically for weight management has more than doubled, reaching 12.4 percent. Women remain the leading users at 15.2 percent, while male usage has also risen sharply to 9.7 percent. This surge in use correlates with a higher public awareness of these treatments, now known to nearly 90 percent of US adults.
Obesity decline across middle age groups
The most notable drops in obesity rates have been recorded among people aged 40 to 64. Those aged 50 to 64 saw a five point decrease, while rates among the 40 to 49 group fell by 4.3 points. These groups also report the highest use of weight loss injectables. Meanwhile, younger adults and seniors show minimal changes, as older adults report lower effectiveness from GLP 1 medicines.
A complex path ahead
Experts caution that while weight loss injections can improve health outcomes, they are not a cure for chronic conditions like diabetes. Expanding coverage for these drugs, along with promoting healthier habits, may determine whether the current decline in obesity becomes a lasting victory for public health.